Pfizer’s RSV vaccine shows promising results in older adults
Pfizer’s Abrysvo vaccine has shown durable protection for older adults against respiratory syncytial virus, with consistent efficacy across two full seasons. Initial data on more than 37,000 participants indicates 77.8% effectiveness against severe illness after the second season, down from 88.9% after one season. The vaccine also demonstrated consistent efficacy against RSV A and RSV B, with no new adverse events reported after the two seasons.
Experts Debunk Claims that mRNA COVID-19 Vaccines Have Caused More Deaths than Saved Lives
Experts have debunked claims that mRNA COVID-19 vaccines have caused more deaths than saved lives, asserting that the vaccines have actually saved millions of lives. Despite social media posts alleging harm, experts emphasize that the vaccines have undergone rigorous testing and monitoring, with public health experts worldwide attesting to their safety and effectiveness. It is crucial to rely on accurate information and facts when it comes to public health issues, especially in the midst of a global pandemic.